Clinical characteristics and outcome of childhood de novo acute myeloid leukemia in Saudi Arabia: A multicenter SAPHOS leukemia group study

被引:14
|
作者
Jastaniah, Wasil [1 ,2 ]
Al Ghemlas, Ibrahim [3 ,4 ]
Al Daama, Saad [5 ]
Ballourah, Walid [6 ]
Bayoumy, Mohammad [7 ]
Al-Anzi, Faisal [8 ]
Al Shareef, Omar [9 ]
Alsultan, Abdulrahman [10 ]
Abrar, Mohammed Burhan [2 ]
Al Sudairy, Reem [11 ]
机构
[1] Umm AlQura Univ, Fac Med, Dept Pediat, Mecca, Saudi Arabia
[2] King Abdul Aziz Med City, Princess Noorah Oncol Ctr, Jeddah, Saudi Arabia
[3] King Faisal Specialist Hosp & Res Ctr, Riyadh, Saudi Arabia
[4] Alfaisal Univ, Fac Med, Riyadh, Saudi Arabia
[5] King Fahad Specialist Hosp, Dammam, Saudi Arabia
[6] King Fahad Med City, Riyadh, Saudi Arabia
[7] King Faisal Specialist Hosp & Res Ctr, Jeddah, Saudi Arabia
[8] Prince Faisal Bin Bandar Canc Ctr, Qaseem, Saudi Arabia
[9] Prince Sultan Mil Med City, Riyadh, Saudi Arabia
[10] King Saud Univ, Coll Med, Dept Pediat, Riyadh, Saudi Arabia
[11] King Abdul Aziz Med City, King Abdullah Specialized Childrens Hosp, Dept Pediat Hematol Oncol, Riyadh, Saudi Arabia
关键词
AML; Acute leukemia; Ethnic; Response; Risk; Developing; CHILDRENS-ONCOLOGY-GROUP; BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; PEDIATRIC AML; CURRENT CONTROVERSIES; SUPPORTIVE CARE; CANCER-GROUP; TRIAL; RISK; ADOLESCENTS;
D O I
10.1016/j.leukres.2016.08.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Geographic variation and ethnicity have been implicated to influence the outcome of pediatric acute myeloid leukemia (AML). Furthermore, survival outcomes from developing countries are reported to be inferior to developed nations. We hypothesized that risk-and response-based outcome in high-income resource-rich developing countries would be comparable to developed nations as access to care and supportive measures would be similar. A total of 193 children diagnosed with de novo AML between January 2005 and December 2012 were identified, of those 175 were evaluable for outcome. Patients were stratified into low-risk (LR), intermediate-risk (IR), or high-risk (HR) groups. The complete remission (CR), early death, and induction failure rates were: 85.7%, 2.3%, and 12%; respectively. The 5-year cumulative incidences of relapse (CIR) and non-relapse mortality (NRM) were 43.1% and 9.8% respectively; overall survival (OS) was 58.8 +/- 4% and event-free survival (EFS) 40.9 +/- 4.1%. The 5-year OS for LR, IR, and HR groups were 72.0 +/- 6.9%, 59.8 +/- 6.2%, and 45.1 +/- 7.4%; respectively (p = 0.003); and EFS 50.5 +/- 8.0%, 46.3 +/- 6.4%, and 23.3 +/- 6.4%; respectively (p = 0.001). This study demonstrated comparable outcomes to those reported from developed countries. This suggests that utilization of risk-and response based protocols in developing countries can overcome ethnic and geographic variation, if access to care and supportive measures were similar. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:66 / 72
页数:7
相关论文
共 50 条
  • [41] The Clinical Characteristics, Genetic Alterations and Prognostic Significance of De Novo Acute Myeloid Leukemia (AML) with Hyperleukocytosis (HL)
    Tien, Feng-Ming
    Hou, Hsin-An
    Chen, Chien-Yuan
    Chou, Wen-Chien
    Li, Chi-Cheng
    Lin, Chien-Ting
    Yao, Ming
    Huang, Shang-Yi
    Ko, Bor-Sheng
    Hsu, Szu-Chun
    Wu, Shang-Ju
    Tsay, Woei
    Tang, Jih-Luh
    Tien, Hwei-Fang
    BLOOD, 2016, 128 (22)
  • [43] Philadelphia Chromosome Positive de novo Acute Myeloid Leukemia
    Quraishi, Arif Moin
    Akram, Muhammad
    Saeed, Sarah
    Tahir, Muhammad
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2016, 26 (11): : S100 - S102
  • [44] De novo acute myeloid leukemia with monocytoid blasts and erythrophagocytosis
    Blieden, Clifford
    Fan, Yao-Shan
    Chapman, Jennifer Rose
    Vega, Francisco
    CLINICAL CASE REPORTS, 2014, 2 (06): : 333 - 335
  • [45] Proteomic Landscape of De Novo Pediatric Acute Myeloid Leukemia
    Hoff, Fieke W.
    Qiu, Yihua
    Hu, Wendy
    Qutub, Amina A.
    Gamis, Alan S.
    Aplenc, Richard
    Kolb, E. Anders
    Alonzo, Todd A.
    de Bont, Eveline S.
    Horton, Terzah M.
    Kornblau, Steven M.
    BLOOD, 2018, 132
  • [46] Nucleophosmin mutation in de-novo acute myeloid leukemia
    Rastogi, Pulkit
    Naseem, Shano
    Varma, Neelam
    Varma, Subhash
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 (01) : 77 - 85
  • [47] CLINICAL CHARACTERISTICS AND CYTOGENETIC ABNORMALITIES OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS: SINGLE INSTITUTE EXPERIENCE FROM SAUDI ARABIA
    Alkhayat, N.
    Elyamany, G.
    Elborai, Y.
    Alsharif, O.
    Awad, M.
    Alsuhaibani, O.
    Bouhajar, I. Ben-Abdallah
    Al Mussaed, E.
    ALshahrani, M.
    HAEMATOLOGICA, 2015, 100 : 642 - 642
  • [48] Proteomic landscape of de novo pediatric acute myeloid leukemia
    Hoff, Fieke W.
    Qiu, Yihua
    Hu, Wendy
    Qutub, Amina A.
    Gamis, Alan S.
    Aplenc, Richard
    Kolb, E. Anders
    Alonzo, Todd A.
    de Bont, Eveline S. J. M.
    Horton, Terzah M.
    Kornblau, Steven M.
    CANCER RESEARCH, 2018, 78 (13)
  • [49] Presentation of de novo acute myeloid leukemia cases carrying NK/myeloid precursor characteristics.
    Salamanchuk, Z
    Zdzilowska, E
    Mensah, P
    Nowak, W
    Skotnicki, AB
    BLOOD, 2001, 98 (11) : 194B - 194B
  • [50] Clinical Significance of Myeloblasts Percentage in the De Novo Acute Myeloid Leukemia with Erythroid Hyperplasia
    Qiu, Shaowei
    Wei, Hui
    Lin, Dong
    Zhang, Guangji
    Wei, Shuning
    Zhou, Chunlin
    Liu, Kaiqi
    Wang, Ying
    Liu, Bingcheng
    Liu, Yuntao
    Gong, Benfa
    Gong, Xiaoyuan
    Feng, Sizhou
    Mi, Yingchang
    Han, Mingzhe
    Wang, Jianxiang
    BLOOD, 2016, 128 (22)